Blarcamesine is a sigma 1 receptor agonist which targets Alzheimer's pathology upstream of amyloid and tau pathology.
SAN DIEGO -- Biomarker and cognitive data supported treatment with the anti-amyloid agent lecanemab (Leqembi) for up to 36 ...
Money Talks News on MSN1d
Having This Type of Body Fat in Mid-Life Is Linked to Alzheimer’sHigh levels of “hidden” fat known as visceral fat may put you at higher risk for Alzheimer’s disease up to two decades before ...
First author Hamilton Oh, now at Icahn School of Medicine at Mt. Sinai, New York, and colleagues identified these potential markers during a proteomics analysis of CSF from 3,397 participants in six ...
Roche's trontinemab data showed dose-dependent amyloid reduction in Alzheimer's patients, while its Elecsys pTau181 test aims ...
Insoluble tau aggregates, particularly neurofibrillary tangles, play a crucial role in the pathology of Alzheimer’s disease. These aggregates correlate closely with the clinical symptoms of the ...
The assays measure phosphorylated tau 181 and apolipoprotein 4 to rule out whether a patient has Alzheimer's disease.
Genentech announced that new data were presented at the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s ...
Roche presented new data at the AD/PD 2025 International Conference demonstrating that trontinemab, in its Phase Ib/IIa Brainshuttle™ AD study, ...
Swiss pharma giant Roche’s Genentech subsidiary has presented new data at the AD/PD 2025 International Conference on ...
Dementia affects millions of people worldwide, causing a serious impact on the economy and the healthcare system. Alzheimer’s ...
New trontinemab data continue to support rapid and deep, dose-dependent reduction of amyloid plaques in Phase Ib/IIa Brainshuttle™ AD study – ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback